Topic Archives: Matt McCall

I recently added a new cryptocurrency recommendation to my model portfolio. This cryptocurrency has soared an amazing 809% over the past 12 months. This nearly tenfold gain is incredible on its own, but it’s even more impressive when you consider it includes the recent coronavirus market “dip.” I’ve been telling readers to get in on […]

Every year we call out a “turkey” stock teaser around Thanksgiving time and poke a bit of fun at some terrible investment ideas… … so it seems only fair to highlight a few winners as well, and this week, when we’re otherwise closed for the holiday, seems a good time to spread some cheer and […]

What have we learned about teaser ads over the past decade or so? A lot, I hope, but two lessons stand out: First, dates in teaser ads are often made up and don’t really represent meaningful “catalyst” events, they’re just a way to make you feel rushed and get you to pull out your credit […]

Matt McCall is touting a tiny company that has created a miracle battery that is safe, inexpensive, more powerful, charges super fast, can charge millions of times without degrading, etc. What’s the symbol?

Here’s a bit from the email that Matt McCall sent out introducing his lastest teaser ad: “When it comes down to it, there are really just three ways to get truly rich in the stock market. You can put thousands into the market every year, hold for decades, and retire with a fortune. You can […]

Matt McCall’s entry level newsletter Investment Opportunities (currently $49/year) is being advertised with a promised “free” special report about the three stocks you need to own before more states legalize sports betting… perhaps as soon as September 6. What’s so special about September 6? That’s just a guess that more attention will come to this […]

As a reformed academic, I have it hard-wired in my brain that work should cease for the week between Christmas and New Year’s Day — Stock Gumshoe will be running on autopilot starting this afternoon, and we’re not likely to have much in the way of new articles posted until next year (unless you want […]

FUTR Stands for “Flying Under The Radar” — Matt McCall says he uses screening to identify fundamentally attractive stocks, and technical analysis to find stocks ready to “break out” with a specific catalyst for growth. Two issues a month, two stock recommendations in each issue.

Comments

  • Avatar

    Steve take a look at Travis Real Money Portfolio. The spreadsheet has 3 of those stocks with stop loss triggers from Tra...

  • Avatar

    $FYI - PV-Tech Newsletter: US Edition - 4/11/2019 Some of todays articles; China to back-up Jinko and LONGi in...

  • Travis Johnson, Stock Gumshoe
  • Travis Johnson, Stock Gumshoe

    It is not necessarily profitable to predict recessions, and it is also almost impossible to do so with any degree of acc...

  • Avatar

    What I am not sure on is do they pay 11% per month on Rent Checks From the Government REIT's or is it accrued for the ye...

  • LongOnLife

    Any "cure" for any potentially fatal disease would be a tremendous blockbuster for the company that develops it. It is t...

  • Avatar

    I laughed out loud too. I love how Travis’s tears these newsletters apart. But I’m not sure which is worse - inve...

  • Avatar

    Fire Arm Daily Please find below a message from our advertising sponsor. Our email newsletter is a free service to you ...

  • Travis Johnson, Stock Gumshoe

    Weather forecasters have made amazing progress using "big data," probably much more than most investment forecasters -- ...

  • Avatar

    Speaking of "security", how secure are our finances in light of: "New Law Gives Banks Ability to Seize Your Accounts"...

  • Avatar

    I've gotten the new pitch for the same thing with a "Act before Feb. 19th" pitch. Thanks for the info....

  • Avatar

    The situation has been created by 50 years of unlimited debt spending with the Congress being bought off and derelict in...

  • Avatar

    Gumshoe, you are AWESOME!!! I think people like Zachary Scheidt should be thrown in Jail for scamming innocent people. T...

  • Avatar

    William, I thank you kindly for your advice and hope to act early in Feb. Sonny...

  • Avatar

    James Altucher is not eccentric, unconventional or a kook. In my opinion, this is all an act. He thinks his acting will...

  • Avatar

    Many years ago,I subscribed to the Weiss Ultimate Portfolio. Their strategy of only buying stocks with the highest WEI...

  • Avatar

    Left identified INGN as his next short target, May 24 when it was at 170. It momentarily dropped to 157 but then went o...

  • Avatar

    Travis, Thanks for great honest writings and insights. Just a question: Instead of wait for your weekly update. Is it po...

  • Avatar

    Interesting, since I do like everything not of this planet. It will be interesting to see which occurs first...a drug c...

  • Avatar
  • Avatar
  • Avatar

    Yes where is my late checks of $2748.00?...

  • Avatar

    Writing is very good. Both Rickards and King graduated from big time law schools, they have been trained to write convi...

  • Avatar

    Just got a chance to listen to Trevena(TRVN)Jefferies presentation by Max Gowen(who is a great speaker and leading this ...

  • Avatar

    Nice article on Actavis (ACT). http://www.ft.com/intl/cms/s/0/472bfe98-d279-11e4-ae91-00144feab7de.html?ftcamp=crm/emai...

  • Avatar

    Actavis (ACT) price target raised to 373.00 by BMO Capital. http://www.americanbankingnews.com/2015/03/18/actavis-plc-p...

  • Dr. KSS, MD PhD

    Actavis $ACT to issue $20B in corporate bonds. Not sure what big deal Brent Saunders is mulling next, but it is likely t...

  • Dr. KSS, MD PhD

    I went long on Irish roll-up Actavis $ACT last year as a speculation on it being a lovely tax inversion play for a US ma...

  • Avatar

    Actavis (ACT) swallowing companies left and right. http://www.ddn-news.com/index.php?newsarticle=9210 Cheers,Glenn...

  • Dr. KSS, MD PhD

    Hi all: My respect goes out to the retired and active service military members here, for doing something I would not ...

  • Dr. KSS, MD PhD

    A couple of updates: GILD shares are sagging in part on concern that ABBV, whose HCV regimen is up for FDA approval ...

  • Avatar

    YES!!!! Durata Therapeutics to be acquired by Actavis (ACT) for $23.00/share in cash, or ~$675 million in the aggregate...

  • Dr. KSS, MD PhD

    $PFE to do tax inversion takeover of Actavis $ACT? Would be quite good fit, I feel....

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch